Literature DB >> 11468192

Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin.

T Daley1, D D Metcalfe, C Akin.   

Abstract

Gain-of-function mutations in c-kit, which appear to contribute to mast cell hyperplasia, have been detected in both limited and aggressive forms of mastocytosis, suggesting that other mutations or polymorphisms may contribute to the clinical phenotype. Because addition of interleukin-4 (IL-4) to mast cell cultures is reported to induce apoptosis, the hypothesis was considered that individuals carrying the gain-of-function polymorphism Q576R in the cytoplasmic domain of the alpha-subunit of the IL-4 receptor (IL-4R) might be relatively resistant to the gain-of-function mutation in c-kit. To assess this possibility, 36 patients with either cutaneous or systemic mastocytosis were studied for association with the Q576R polymorphism. The Q576R polymorphism was found more frequently in those with disease limited to skin and who exhibited lower levels of surrogate disease markers. These data suggest that the Q576R IL-4R alpha- chain polymorphism may mitigate disease expression and confer a better prognosis in patients with mastocytosis. (Blood. 2001;98:880-882)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468192     DOI: 10.1182/blood.v98.3.880

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Mastocytosis and disorders of mast cell proliferation.

Authors:  Joanne K Simpson; Dean D Metcalfe
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

Review 3.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

Review 4.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

5.  Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis.

Authors:  Gabriella Galatà; Andrés C García-Montero; Thomas Kristensen; Ahmed A Z Dawoud; Javier I Muñoz-González; Manja Meggendorfer; Paola Guglielmelli; Yvette Hoade; Ivan Alvarez-Twose; Christian Gieger; Konstantin Strauch; Luigi Ferrucci; Toshiko Tanaka; Stefania Bandinelli; Theresia M Schnurr; Torsten Haferlach; Sigurd Broesby-Olsen; Hanne Vestergaard; Michael Boe Møller; Carsten Bindslev-Jensen; Alessandro M Vannucchi; Alberto Orfao; Deepti Radia; Andreas Reiter; Andrew J Chase; Nicholas C P Cross; William J Tapper
Journal:  Am J Hum Genet       Date:  2021-01-08       Impact factor: 11.025

Review 6.  Mastocytosis.

Authors:  Knut Brockow; Dean D Metcalfe
Journal:  Chem Immunol Allergy       Date:  2010-06-01

7.  An atopy-associated polymorphism in the ectodomain of the IL-4R(alpha) chain (V50) regulates the persistence of STAT6 phosphorylation.

Authors:  Andrew Q Ford; Nicola M Heller; Linda Stephenson; Mark R Boothby; Achsah D Keegan
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

8.  Regulation of normal and neoplastic human mast cell development in mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

9.  CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Authors:  Niklas Mueller; Daniel Wicklein; Gregor Eisenwort; Mohamad Jawhar; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Alexandra Boehm; Christoph Kornauth; Leonhard Muellauer; Susanne Sehner; Gregor Hoermann; Wolfgang R Sperr; Philipp B Staber; Ulrich Jaeger; Johannes Zuber; Michel Arock; Udo Schumacher; Andreas Reiter; Peter Valent
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

Review 10.  Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders.

Authors:  P Valent
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.